The Latest Cardiac and Vascular News
A cash position of €15.4 million at June 30, 2022. Financial visibility until the last quarter of 2023, excluding potential additional revenues. Continued execution of the strategic and operational roadmap for future commercialization. LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL / PEA/SME eligible) (Paris:ALVAL), a Research and Development […]
All Merger-related proposals approved at the Annual Meeting of Stockholders BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders […]
Leadership Team Continues to Expand with Addition of Key Leader in Clinical Operations “Julie brings nearly two decades of clinical development operations experience to DiaMedica across a wide breadth of pharmaceutical therapeutic areas, including Phase 3 pivotal programs. She is an expert in trial execution and management of the myriad […]
MIAMI, Sept. 13, 2022 /PRNewswire/ — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced that it has raised an additional $10.5 million, bringing its cumulative financing to over $25 million. The financing was led by Syntheon and Santé Ventures who were joined by Epidarex Capital, Hatteras Venture Partners, and Broadview Ventures. RapidPulse plans […]
VILLANOVA, Pa., Sept. 13, 2022 /PRNewswire/ — Prolifagen Therapeutics, a biotech startup developing medicines for cardiac regeneration, has appointed M. Alexander Shaw, PhD, as Chief Executive Officer. In this role, Dr. Shaw will lead Prolifagen’s efforts in bringing new medicines to market to prevent development of heart failure in patients with large myocardial […]
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year Southlake, Texas, Sept. 13, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company […]
Combined Company Dedicated to Developing and Delivering Novel Technologies and Solutions to Improve the Lives of Patients with Cardiac Arrhythmias Medtech Veteran David Jenkins to Lead Merged Company CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces it has entered into an Agreement and Plan […]
Strategic Investment Expected to Help Accelerate Cardiac Monitoring and Strategic Relationship Aims to Create Improved Disease State Treatment Models SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced the completion of an investment funded by Health Insight Capital, the investment arm of HCA […]
alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON study in Q4 2022 DSR® – clinical evidence of disease-modifying heart failure drug therapy / preparations ongoing to start US phase 1b/2a MOJAVE study in H1 2023 Total liquidity position of €23.8 million and cash runway into Q3 2023 Conference call with live webcast presentation today at 03:00 pm CET / 09:00 am ET Ghent, Belgium – 8 September 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” […]
A global leader in the endovascular space will collaborate with the Company as it goes through the regulatory process and future commercialization HINGHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a reputation within the interventional radiology community for its LIBERTY® Robotic System, […]
